Clinical Scorecard: New Evidence Challenging the Inclusion of Cyproterone Acetate in Gender-Affirming Hormonal Treatment Protocols

At a Glance

Key Highlights

• No significant difference in breast growth or patient-reported breast satisfaction between cyproterone acetate and spironolactone over 6 months.
• Cyproterone acetate more effectively suppresses serum testosterone than spironolactone at studied doses.
• Cyproterone acetate is associated with potential adverse effects including dyslipidemia, mild hyperprolactinemia, and rare meningioma formation.

Guideline-Based Recommendations

Diagnosis

• Assess baseline hormone levels and breast development status prior to initiating adjunct antiandrogen therapy.

Management

• Consider spironolactone as the preferred adjunct antiandrogen due to better safety profile and FDA approval status in the US.
• Individualize antiandrogen choice through shared decision-making, weighing benefits and risks.
• Monitor estradiol dosing to achieve adequate testosterone suppression, especially if using spironolactone.

Monitoring & Follow-up

• Regularly monitor serum testosterone and estradiol levels to guide therapy adjustments.
• Monitor for adverse effects including hyperkalemia with spironolactone and dyslipidemia or prolactin elevation with cyproterone acetate.
• Assess patient-reported outcomes including breast satisfaction and cognitive symptoms.

Risks

• Cyproterone acetate may increase risk of coronary artery disease, breast cancer, venous thromboembolism, and meningioma.
• Spironolactone carries risk of rare but potentially fatal hyperkalemia.
• Potential cognitive side effects ('brain fog') with spironolactone not supported by current evidence.

Patient & Prescribing Data

Transfeminine individuals receiving feminizing hormone therapy with adjunct antiandrogens

Both cyproterone acetate and spironolactone yield similar breast development outcomes; spironolactone preferred due to safety and regulatory status.

Clinical Best Practices

• Use shared decision-making to select adjunct antiandrogen therapy based on individual risk profiles and patient preferences.
• Titrate estradiol dosing to achieve optimal testosterone suppression regardless of antiandrogen choice.
• Monitor for and manage potential adverse effects specific to each antiandrogen agent.
• Educate patients on the lack of evidence for superior breast growth with cyproterone acetate compared to spironolactone.

References

• Angus et al. Effect of Spironolactone and Cyproterone Acetate on Breast Growth in Transgender People: A Randomized Clinical Trial
• Evidence linking cyproterone acetate to dyslipidemia, hyperprolactinemia, and meningioma
• Risks of progestogens in hormone replacement therapy
• Spironolactone safety and hyperkalemia risk